No­var­tis wins big in head-to-head Eylea matchup, set­ting up a loom­ing mar­ket feud with Re­gen­eron

No­var­tis in­ves­ti­ga­tors went head-to-head with Re­gen­eron’s block­buster Eylea in two large Phase III stud­ies. And they scored, scoop­ing up promis­ing top-line re­sults and set­ting up a 2018 fil­ing that puts them on a col­li­sion course with the big biotech.

The phar­ma gi­ant an­nounced this morn­ing that it had hit the pri­ma­ry — non-in­fe­ri­or­i­ty to Eylea — and sec­ondary end­points with RTH258 among 1,800 pa­tients with neo­vas­cu­lar age-re­lat­ed mac­u­lar de­gen­er­a­tion (nAMD) across 400 cen­ters world­wide.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER